Navigation Links
A potent suppressor of endometrial cancer is revealed
Date:2/8/2010

Endometrial cancer is the most common cancer of the female reproductive tract, representing 6% of all cancers. There is currently no screening method or biomarker to indicate early presence of disease. "It is a very common malignancy that affects women of all ages" comments paper author Dr. Diego Castrillon. The cancer forms from the cells that grow along the inner lining of the uterus, which is called the endometrium, and usually it is diagnosed following patient reports of abnormal bleeding.

The normal endometrium is a dynamic place, providing a thick, highly vascularized environment ready to generate a placenta if it is implanted with an embryo. The dynamic and cyclic activity of the endometrium makes it very sensitive to signaling molecules. Early changes in a number of signaling proteins are known to contribute to endometrial cancer in some patients. A major research goal is to understand how signals create cancer cells and to identify places where intervention might shut down the signals that promote cancer cell survival and growth.

Researchers learn about cancer by creating genetic changes to signaling proteins in mice that reflect changes found in human cancer patients. Animal models are produced in this way to help understand how cancer cells form and progress. One challenge is to localize genetic changes to the environment of interest. In the case of endometrial cancer, researchers need to specifically modify only those cells that are in the endometrium, so that their data is not complicated by changes in other tissues.

In a new study published in Disease Models & Mechanisms (DMM), <http://dmm.biologists.org/>, scientists report a new genetic tool that can specifically alter gene expression in the endometrium. They use this approach to remove a signaling protein gene only in endometrial cells to determine its influence on endometrial cancer formation. They found that the genetic change induced a very rapidly progressing cancer in all mice that carried the mutation. The gene they deleted, called Lkb1, is mutated in many other types of human cancers, and it regulates pathways that are known to contribute to the formation of aggressive cancer cells.

Very few genetic changes act alone to induce cancer. Most cancer cells result from multiple mutations. However, all mice deficient for just Lkb1, exhibited cancerous changes throughout their entire endometrium. "In most mouse cancer models, one creates a tumor prone condition. But additional mutations are usually required for a cell to develop a cancer" says Dr. Castrillon, "What is surprising about the Lkb1 model, is that their entire endometrium becomes malignant. It happens very early and rapidly."

The rapid development of cancer in mice without Lkb1 suggests that this gene or the molecules that its product regulates may be valuable targets for future therapy. The authors show that treating the mice with a drug that blocks a downstream target of the Lkb1 product kills tumor cells, leading to tumor shrinkage and dramatic recovery of the mice. "It is likely that this pathway is very important. We believe that Lkb1 mutations or mutations in other steps in this pathway represent some type of metabolic abnormality that we could take advantage of [for therapeutic intervention]" says Dr. Castrillon.


'/>"/>

Contact: Kristy Kain
kristy.kain@vanderbilt.edu
615-343-1298
The Company of Biologists
Source:Eurekalert

Related biology news :

1. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
2. Neuronal conduction of excitation without action potentials based on ceramide production
3. To maximize biofuel potential, researchers look for sorghums sweet spot
4. Joslin researchers uncover potential role of leptin in diabetes
5. Chemistry turns killer gas into potential cure
6. Researchers examine worlds potential to produce biodiesel
7. New inhibitor has potential as cancer drug
8. Potential new therapeutic molecular target to fight cancer
9. WCS study finds potential to double tiger numbers in South Asia
10. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
11. Great potential to improve collection, recycling of Europes electronic waste, says UN report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... New York, NY (PRWEB) , ... October 12, ... ... York Academy of Sciences today announced the three Winners and six Finalists of ... Awards are given annually by the Blavatnik Family Foundation and administered by the ...
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... ... 2017 , ... Proscia Inc ., a data solutions ... “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, Managing ... how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology: